EDSA: Edesa Biotech Inc Company Value to Net Income
The visual representation of Edesa Biotech, Inc. (EDSA) quotes with the -2.10 metric demonstrates the dynamics of the biopharmaceutical business. The firm's prospects rely on the efficacy of EB05 in treating severe lung injuries. Risks are mitigated by a broad spectrum of developments for the skin and respiratory organs. However, the absence of commercial products nullifies cash flow, making the structure's viability entirely dependent on external financing.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_EDSA_-_Edesa-Biotech-Inc._-_PE-Multiple "EDSA: Edesa Biotech, Inc. Business Payback Period 07/04/2022 - 11/12/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Edesa (EDSA)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
- earnings and market multiples details:
EDSA - Net Profit|Net Profit Forecast Edesa Biotech, Inc.|EDSA - P/E Multiple|Projected Price to Earnings Ratio Edesa Biotech Inc|EDSA - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Edesa Biotech, Inc.|EDSA - Operating profit EBITDA|Net earnings per share (EPS TTM) Edesa Biotech|EDSA - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months edesabiotech.com|EDSA - Earnings growth in current year|Net earnings per share growth forecast for next year Edesa Biotech, Inc.
Comprehensive company analysis:edesabiotech.com EDSA
For Edesa Biotech, Inc. (EDSA), which focuses on developing therapies for inflammatory diseases, the company's P/E ratio reflects market expectations regarding the success of clinical trials and future regulatory approvals. This metric compares current market capitalization with annual net income, allowing investors to assess the cost of each unit of earnings and determine the extent to which the asset is overbought relative to its actual financial performance.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|AbCellera Bio - P/E Multiple|Market Cap to Earnings Tourmaline|PGEN: P/E Multiple|Price to Earnings Multiple PHAR|NKTR (Nektar Therapeutics Inc.) - P/E Multiple|Market Cap to Earnings Upstream Bio, Inc. UPB|Price to Earnings Ratio Zenas Biopharma, Inc. (ZBIO)|Business Payback Period Immunome Bio|P/E Multiple GOSS (Gossamer Bio, Inc.)|P/E Multiple kalvista.com KALV|SEPN: Price to Earnings Ratio|Company Value to Net Income PVLA (Pieris Pharma)|SVRA: P/E Multiple|RIGL (Rigel Corp) - Price to Earnings Ratio|ANAB (AnaptysBio, Inc.) - P/E Multiple|astriatx.com (ATXS) - Business Payback Period|Price to Earnings Ratio enGene (ENGN)|RAPT - Market Cap to Earnings|Aerovate Therapeutics - Price to Earnings Ratio|Market Price to Net Income Ratio ACRS (Aclaris Therapeutics, Inc)|Kyverna Therapeutics - P/E Multiple|Market Cap to Earnings tizianalifesciences.com|CABA: P/E Multiple|Price to Earnings Ratio Ventyx Biosciences Inc.|THTX (Theratechnologies Inc) - P/E Multiple|AVTX: Company Value to Net Income|Price to Earnings Ratio ELDN (Eledon Pharmaceuticals)|AGEN (agenusbio.com) - Company Value to Net Income|P/E Multiple CLYM (Climb Bio)|Business Payback Period Zura Bio Ltd (ZURA)|ATYR - Price to Earnings Ratio|ADAG (Adagene) - Price to Earnings Multiple|IMA: P/E Multiple|Price to Earnings Ratio Shattuck Labs|Price to Earnings Ratio EQ|Connect Pharma (CNTB) - Business Payback Period|P/E Multiple IMUX|ATRA - Market Cap to Earnings|P/E Multiple IFRX (InflaRx)|XFOR: Price to Earnings Multiple|ACET - Price to Earnings Ratio|Business Payback Period Celularity Inc. CELU|INMB: P/E Multiple|Barinthus Biotherapeutics Corp (BRNS) - P/E Multiple|Price to Earnings Ratio Kezar Life Sciences|sabbiotherapeutics.com - Market Cap to Net Income|P/E Multiple AKTX|ENLV (enlivex.com) - Company Value to Net Income|P/E Multiple QTTB (Q32 Bio)|P/E Multiple GeoVax Corp GOVX|IBIO - Price to Earnings Ratio|Company Value to Net Income CARM (Carisma Therapeutics)|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Price to Earnings Ratio Bolt Biotherapeutics, Inc.|HCWB (HCW Biologics, Inc.) - P/E Multiple|P/E Multiple Aptevo|Price to Earnings Ratio AIM (AIM ImmunoTech Inc.)|ADTX (aditxt.com) - Company Value to Net Income|P/E Multiple GRI (GRI Bio)|Business Payback Period XORTX Therapeutics Inc (XRTX)|HIND - Price to Earnings Ratio|Revelation Biosciences Corp (REVB) - Price to Earnings Ratio|Indaptus Therapeutics (INDP) - Price to Earnings Ratio|Price to Earnings Ratio scinai.com|Price to Earnings Ratio CALI|P/E Multiple Affimed Therapeutics|Price to Earnings Ratio Allakos Inc. (ALLK)|hookipapharma.com - Price to Earnings Multiple|P/E Multiple IGMS (IGM Biosciences)|iteostherapeutics.com (ITOS) - Market Cap to Earnings|Ocean Biomedical - P/E Multiple|Market Cap to Earnings TC BioPharm (Holdings) Plc|THRD: P/E Multiple
